MEDITECH(SH:603990)2025-10-29 10:25Revenue and Profitability - Revenue for Q3 2025 was CNY 87,708,575.06, a decrease of 15.68% compared to the same period last year[3] - Year-to-date revenue reached CNY 222,912,349.82, down 38.13% year-over-year[3] - Net profit attributable to shareholders for Q3 2025 was CNY 5,942,355.49, with a year-to-date net profit of CNY 34,269,812.83[3] - Basic earnings per share for Q3 2025 was CNY 0.02, unchanged from the previous period[4] - The company reported a net loss of CNY 204,554,988.59 for the first three quarters of 2025, an improvement from a net loss of CNY 238,824,801.42 in the same period of 2024[13] - The net profit for the first three quarters of 2025 is CNY 36,097,511.29, a significant recovery from a net loss of CNY -166,251,751.36 in the same period of 2024[15] - Operating profit for the current period is CNY 38,512,946.55, compared to a loss of CNY -159,160,870.71 in the previous year[15] - The total comprehensive income for the current period is CNY 36,097,511.29, compared to a total comprehensive loss of CNY -166,251,751.36 in the same period last year[16] Cash Flow and Liquidity - The company reported a significant improvement in cash flow from operating activities, with a net cash flow of CNY 12,812,043.23 year-to-date[3] - Cash flow from operating activities shows a net inflow of CNY 12,812,043.23, improving from a net outflow of CNY -45,585,403.83 in the prior year[17] - Cash flow from investing activities has a net inflow of CNY 225,523,580.03, recovering from a net outflow of CNY -72,306,847.78 in the same period last year[18] - Total cash and cash equivalents at the end of the period stand at CNY 239,632,571.26, up from CNY 144,121,483.02 at the end of the previous year[18] - Cash and cash equivalents increased to CNY 252,445,201.14 as of September 30, 2025, compared to CNY 119,336,851.27 at the end of 2024, representing a growth of 111.4%[11] - The company has reported a decrease in cash received from tax refunds to CNY 7,866,080.63 from CNY 151,795,357.26 in the previous year[17] Assets and Liabilities - Total assets decreased by 60.55% to CNY 1,248,366,147.81 compared to the end of the previous year[4] - Total assets decreased to CNY 1,248,366,147.81 as of September 30, 2025, down from CNY 3,164,052,059.39 at the end of 2024[12] - Total liabilities decreased to CNY 404,569,775.22 as of September 30, 2025, compared to CNY 2,359,264,396.45 at the end of 2024[12] - The company’s total equity increased to CNY 843,796,372.59 as of September 30, 2025, compared to CNY 804,787,662.94 at the end of 2024[13] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.27% to CNY 833,813,770.16[4] - The total number of ordinary shareholders at the end of the reporting period was 38,943[9] Operational Performance - The disposal of the photovoltaic business in January 2025 led to a reduction in operational losses and a return to profitability in the medical sector[7] - Total operating revenue for the first three quarters of 2025 was CNY 222,912,349.82, a decrease of 38.1% compared to CNY 360,301,548.27 in the same period of 2024[14] - Total operating costs for the first three quarters of 2025 were CNY 211,917,664.40, down 63.4% from CNY 579,593,276.48 in the previous year[14] - Research and development expenses for the first three quarters of 2025 amounted to CNY 21,794,272.31, a reduction of 49.7% compared to CNY 43,316,194.03 in 2024[14] Investment Performance - The company’s long-term equity investments were valued at CNY 15,039,043.87 as of September 30, 2025, down from CNY 15,942,052.41 at the end of 2024[11] - The company has received CNY 390,000,000.00 from the recovery of investments, compared to CNY 469,000,000.00 in the same period last year[18]